| Dr Robert Nicholas Agnello, DO | |
|
129 Tt Lanier Street, Buies Creek, NC 27506 | |
| (910) 893-1560 | |
| (910) 814-5727 |
| Full Name | Dr Robert Nicholas Agnello |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 129 Tt Lanier Street, Buies Creek, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467434134 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | 2011-00474 (North Carolina) | Secondary |
| 207Q00000X | Family Medicine | 2011-00474 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Nicholas Agnello, DO 108 Spring Pond Ln, Spring Lake, NC 28390-9328 Ph: (910) 813-5391 | Dr Robert Nicholas Agnello, DO 129 Tt Lanier Street, Buies Creek, NC 27506 Ph: (910) 893-1560 |
News Archive
GP training, improved access to memory clinics and a public campaign for awareness are necessary to improve the diagnosis of dementia in the UK, says the All-Party Parliamentary Group on Dementia.
Obstructive sleep apnea is a common and costly medical condition leading to a wide range of health risks such as cardiovascular disease, stroke, depression, diabetes and even premature death.
Treatment of depressive symptoms may help lower the risk of early death in individuals with chronic kidney disease, but racial/ethnic differences may exist. The findings come from a study that will be presented at ASN Kidney Week 2017 October 31–November 5 at the Ernest N. Morial Convention Center in New Orleans, LA.
PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 7 days ago